Day 1 – Wednesday 11th SeptemberWednesday, 11 September 2024 - EST/EDT (Eastern Daylight, GMT-4)

While the excitement and anticipation is huge, what is the actual way forward with AI? How can organisations operationalise it to deliver business and patient benefits?

• Addressing barriers to adoption so we can build out scale with AI
• Exploring the bridge between commercial and R&D
• Maintaining the human touch - How can we use AI to improve the patient experience?
• What are the safeguards for applications of AI?
• AI use in Pharma- Analytics, leveraging RWE, AI modelling and increasing efficiency & effectiveness

• Which digital therapeutics business models are working in the real world? What is the business model of the future?
• Given the issues with reimbursement, what are companies doing to survive?
• DTx-pharma partnerships & collaborations – Are Pharma moving away from DTx?
• Addressing investor hesitancy and raising funds
• Defining clear value proposition to address customers’ unmet needs
• The DTx sweet spot is behavioural health– How can it be applied to other disease areas? How valuable would this be to the healthcare sector?

• Co-creating a solution with patients and medical professionals
• Scaling digital clinical trials solutions
• Achieving diversity, equity, and inclusion in decentralized trials
• Partnering for success- Is a unified digital clinical trial solution the answer?
• Investing in clinical trial tech – investor perspectives

• Adopting a customer-centric approach and transforming the experience of the end user
• How are life science companies continuing to build their digital strategy and capabilities?
• Discussing the persisting challenges in scaling digital and analytics
• Examining the rise in digital software adoption and development objectives
• A look at future digitized go-to-market models for pharma and medtech companies

• Demonstrating real value, a path to profitability and scalable unit economics
• Navigating investment landscapes and securing funding for scale-up initiatives
• Leveraging collaborations for mutual growth and innovation
• Prioritizing user experience in the design and scalability of digital health products
• Ensuring regulatory compliance at scale

• Evaluating digital health and DTx partnerships/ collaborations – how well are they working?
• Navigating diverse partnership models
• Are pharmaceutical companies the preferred partners for digital health start-ups?
• Investor and pharma expectations from digital health companies and vice versa

• Leveraging GenAI tools (including large language models) to optimise care delivery
• The use of GenAI help solve the challenge of patient engagement
• Does the Biden AI framework provide sufficient guardrails for companies? What legislation is needed?
• Scaling up equitable and inclusive AI healthcare models

• What factors are driving digital health investor investment decisions, and which areas are primed for growth?
• Are AI-enabled prescription digital therapeutics an investment priority?
• The continued importance of healthtech and digital health companies demonstrating real value, a path to profitability and scalable unit economics
• Evaluating the investment opportunities in emerging tech
• How do the financial stresses and growing needs of health systems impact the greater digital health investment landscape?